# Perspective Therapeutics

Source: https://onco.cc/companies/perspective-therapeutics/  
OnCo record `perspective-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.

## Summary

Phase 1/2a of [212Pb]VMT-α-NET (NCT05636618): 43% ORR in cohort 2 with 72% progression-free/alive at the 2026 update; 76 NET patients treated by July 2026; first meningioma patient dosed June 2026; EU orphan designation July 2026. Phase 3 planned at a cumulative 20 mCi dose. Also developing PSMA and melanocortin-1 receptor 212Pb agents.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Seattle, WA
- Type: radiopharma
- Website: https://perspectivetherapeutics.com
- Ticker: CATX

## Sources

- Q2 2026 highlights: https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Alpha-emitter nanogenerators and daughter trapping](https://onco.cc/technologies/alpha-nanogenerators/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/), [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- terms: [Alpha vs beta emitters](https://onco.cc/terms/alpha-vs-beta/)
- trials: [Lead-212 PSV359 Therapy for Patients With Solid Tumors](https://onco.cc/trials/nct06710756/), [MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma](https://onco.cc/trials/nct05655312/), [Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors](https://onco.cc/trials/nct05636618/)
- ideas: [Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211](https://onco.cc/ideas/idea-reg-alpha-emitter-portfolio/)

---
JSON: https://onco.cc/api/v1/entities/perspective-therapeutics.json